Expression of metalloproteinases MMP-1 and MMP-9 and tissue inhibator of metalloproteinases TIMP-1 in cases of endometrial carcinoma and endometrial hyperplasia;Ekspresja metaloproteinaz MMP-1, MMP-9 oraz tkankowego inhibitora metaloproteinazy TIMP-1 w przypadkach raka endometrium oraz rozrostów błony śluzowej jamy macicy

Przeglad Menopauzalny

Volumn 5, Issue 6, 2006, Pages 363-366

  Wlaźlak, Edyta ^a   Surkont, Grzegorz ^a   Kobos, Józef ^b   Tyliński, Wiesław ^a   Stetkiewicz, Tomasz ^c   Suzin, Jacek ^a  

^a Medical University of Lodz Klinika Ginekologii i Onkologii Ginekologicznej   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Endometrial cancer; Endometrium; Hyperplastc endometrium; Matrix metalloproteinases; MMPs; TIMPs; Tissue inhibitors of metalloproteinases

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CANCER CELL; CANCER INVASION; CELL COMPARTMENTALIZATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CURETTAGE; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CELL; ENDOMETRIUM HYPERPLASIA; ENZYME ACTIVITY; ENZYME LOCALIZATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; STATISTICAL SIGNIFICANCE; UTERUS CAVITY;

EID: 33846654678     PISSN: 16438876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hacker NF. Uterine cancer. in: Berek JS, Hacker NF. Practical Gynecologic Oncology, Wiliams and Wilkins, 1994, 285-326.
2. Spaczyński M. Epidemiologia nowotworów narzadów płciowych. W: Spaczyński M. Onkologia ginekologiczna. Urban i Partner 1997, 9-16.
3. Gambacciani M, Monteteleone P, Ciaponi M. Clinical usefulness of endometrial screening by ultrasound in asymptomatic postmenopausal women. Maturitas 2004; 48: 421-4.
4. Gerber B. Krause A. Muller H. Ultrasonographic detection of asymptornatic endometrial cancer in postmenopausal patients offers no prognostic advantage over symptomatic disease discovered by uterine bleeding. Eur J Cancer 2001; 37: 64-71.
5. Valentin L. High-quality gynecological ultrasound can be highly beneficial, but poor-quality gynecological ultrasound can do harm. Ultrasound Obstet Gynecol 1999; 13: 1-7.
6. Curry TE, Osteen KG. Cyclic changes in the matrix metalloproteinase system in the ovary and uterus. Biol Reprod 2001; 64: 1285-96.
7. Clark IM, Swingler TE, Young DA. Acetylation in the regulation of metalloproteinase and tissue inhibitor of metalloproteinases gene expression. Front Biosci 2007; 12: 528-35.
8. Verstappen J, von den Hoff JW. Tissue Inhibitors of Metalloproteinases (TIMPs): Their biological functions and involvement in Oral Disease. J Dent Res 2006; 85: 1074-84.
9. Balduyck M, Zerimech F, Gouyer V. Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis 2000; 18: 171-8.
10. Baruch RR, Melinscak H, Lo J. Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation. Cell Biol Int 2001; 25: 411-20.
11. Borden P, Heller R. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryotic Gene Expr 1997; 7: 159-178.
12. Dano K, Romer J, Nielsen BS. Cancer invasion and tissue remodeling - cooperation of protease systems and cell types. APMIS 1999; 107: 120-7.
13. Henriet P, Blavier I, DeClerck YA. Tissue Inhibitors of metalloproteinases (TIMP) and proliferation. APMIS 1999; 107: 111-9.
14. Muller D, LI DQ, Tseng SC. Regulation of collagenase, stromelysin and gelatinase B in human conjunctival and conjunctivochalasis fibroblasts by interteukin 1-beta and tumor necrosis factor alpha. Invest. Ophthalmol Vis Scl 2000; 41: 2922-9.
15. Kunz J. Matrix Metalloproteinases and Atherogenesis in Dependence of Age. Gerontology 2006; 17: 63-73.
16. Lesauskaite V Epistolato MC, Castagnini M, et al. Expression of matrix metalloproteinases, their tissue inhibitors, and osteopontin in the wall of thoracic and abdominal aortas with dilatative pathology. Hum Pathol 2006; 37: 1076-84.
17. Staack A, Badendieck S, Schnorr D, et al. Combined detection of plasma MMP2, MMP9 and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol 2006; 10: 6-19.
18. Ulug U., Godlman S., Ben-Shlomo I. Et al. Matrix metalloproteinase MMP-2 and MMP-9 and their inhibitor, TIMP-1, in human term decidua and fetal membranes: the effect of prostaglandin F2alpha and indomethacin. Mot Hum Reprod 2001; 7: 1187-93.
19. Birkedal-Hansen B, Pavelic ZP, Gluckman JL. MMP and TIMP gene expression in head and neck squamous cell carcinomas and adjacent tissues. Oral Dis 2000; 6: 376-82.
20. Graesslin O, Cortez A, Fauvet R, et al. Metalloproteinaze-2, -7 and -9 and tissue inhibitor of metalloproteinaze-1 and -2 expression in normal, hyperplastic and neoptastic endometrium: a clinical-pathological correlation study. Ann Oncol 2006; 17: 637-45.
21. Maatta M., Soini Y., Liakka A, et al. Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic and neoplastic endometrium. Am J Clin Pathol 2000; 114: 402-11.